Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir™ Versus Continued HAART: The Trizal Study

REFERENCES

• Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of periph-eral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.
   PubMed Web of Science ®Google Scholar
• Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13: 2493–2505.
   PubMed Web of Science ®Google Scholar
• Mauss S. HIV-associated lipodystrophy syndrome. AIDS. 2000;14\(suppl 3):5197–5207.
   Google Scholar
• Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and postheparin lipase activities in normal sub-jects. AIDS. 2000;14:51–57.
   PubMed Web of Science ®Google Scholar
• Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:11–18.
   PubMed Web of Science ®Google Scholar
• Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001;15: 1801–1809.
   PubMed Web of Science ®Google Scholar
• Melial SA, John M, et al. Contribution of nucleoside ana-logue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14: 1309–1316.
   PubMed Web of Science ®Google Scholar
• Yanovski JA, Miller KD, Kino T, et al. Endocrine and meta-bolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated li-podystrophy. J Clin Endocrinol Metab. 1999;84:1925–1931.
   PubMed Web of Science ®Google Scholar
• Reaching a consensus: lipodystrophy case definition. First International Workshop on Adverse Drug Reaction and Lipodystrophy, San Diego. Antiviral Ther. 1999;4\(suppl 2):75–77.
   PubMed Web of Science ®Google Scholar
• Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: switching from successful HAART to TrizivirTm (abacavir-lamivudine-zidovudine combination tablet): 48 weeks effi-cacy, safety and adherence results. Submitted for publica-tion.
   Google Scholar
• Shevitz A, Wanke AW, Falutz J, Kotler DP. Clinical per-spectives on HIV-associated lipodystrophy syndrome: an update. AIDS. 200115:1917–1930.
   Google Scholar
• Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Res. 200151: 151–177.
   Google Scholar
• Cohen C, Shen Y, Rode R, et al. Effect of nucleoside (NRTI) intensification on prevalence of morphologic abnormalities (MoAs) at year 5 of ritonavir (RTV) plus saquinavir (SQV) therapy in an HIV-infected cohort. In: Program and ab-stracts of the Ninth Conference on Retroviruses and Op-portunistic Infections; February 2002; Seattle. Abstract 683–T.
   Google Scholar
• Caron M, Auclair M, Kornprobst M, Capeau J. Step-by step evaluation of the impact of different protease inhibitors on adipogenesis: pathophysiological insights and relevance to the clinic. In: Program and abstracts of the Ninth Confer-ence on Retroviruses and Opportunistic Infections; Febru-ary 2002; Seattle. Abstract 690–T.
   Google Scholar
• Walker UA, Setzer B, Venhoff N. Increased long-term mito-chondrial toxicity in pyrimidine nucleoside combinations. Antiviral Ther. 2001;6\(suppl 4):13–14.
   Google Scholar
• Birkus G, Hitchcock M, Cihlar T. Assessment of mitochon-drial toxicity in human cells treated with tenofovir: compari-son with other nucleoside reverse transcriptase inhibitors. Antimicrobial Agent Chemother. 200246: 716–723.
   Google Scholar
• Shevitz, Wanke CA, Falutz J, Kotler DP. Clinical perspec-tives on HIV-associated lipodystrophy syndrome: an up-date. AIDS. 200115:1917–1930.
   Google Scholar
• John M, Nolan D, Melial S. Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther. 2001;6:9–20.
   PubMed Web of Science ®Google Scholar
• Martinez E, Conget I, Lozano L, et al. Reversion of meta-bolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805–810.
   PubMed Web of Science ®Google Scholar
• Hatano H, Miller KD, Yoder CP, et al. Metabolic and an-thropometric consequences of interruption of highly active antiretroviral therapy. AIDS. 2000;14:1935–1942.
   PubMed Web of Science ®Google Scholar
• Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001;15: 1811–1822.
   PubMed Web of Science ®Google Scholar
• Carr A, Smith D, Workman C, et al. Switching stavudine or zidovudine to abacavir for HIV lipodystrophy: a random-ized, controlled, open-label, multicentre, 24-week study. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 32.
   Google Scholar
• John M, James I, McKinnon E, et al. A randomized, con-trolled, open-label study of revision of antiretroviral regi-mens containing stavudine (d4T) and/or a protease inhibi-tor (P1) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 700–T.
   Google Scholar
• McComsey G, Lonergan T, Fisher R, et al. Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV). In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 701–T.
   Google Scholar